Clinical efficiency of Nigella sativa Linn in novel covid-19: A review study

Abstract

Objective: To evaluate the efficiency of N. sativa in prevention and management of COVID-19. Background: A novel SARS-CoV-2 which is a severe acute respiratory syndrome, was acknowledged as SARS endemic, started in Asia, with the common of cases occurring in China and the Asia–Pacific countries. According to Ministry of Health and Family Welfare, GOI, since the outbreak, of COVID-19 global pandemic, on March 11, 2020, presently at the end of September 2020, total 940441 cases were active and 5187825 cases were cured, and 97497 were dead. Hence counting the number of cases, including mild cases, is necessary to standardize the epidemic response. Most drug designs against 2019-nCoV have been focused on immunomodulators (such as corticosteroids and interferons), monoclonal antibody production, and inhibitory agents against viral proteinase, helicase, and polymerases. However, to date, few specific antiviral treatment or vaccine has been approved by the FDA for COVID-19, but not hundred percent effectiveness has been achieved. Considering the success of AYUSH systems in managing several epidemics and restoring health, AYUSH system recommends some herbs for the treatment of COVID-19. Among them Nigella sativa is one which is Known by the common name